HVivo trading in line with expectations with early success in diversification strategy

hVIVO PLC reported H1 revenue of £24.2 million and EBITDA of £3 million, both down year-on-year, reflecting broader macroeconomic and sector-specific headwinds impacting the CRO industry. Despite this, the company is trading in line with expectations, citing early success in its diversification strategy, which generated £7.9 million from new service lines. A strong pipeline, including a £40 million contracted orderbook and a letter of intent for a pivotal Phase III human challenge trial, positions hVIVO for continued growth amidst market challenges.

Analysis

hVIVO PLC's first-half 2025 results reflect a challenging environment for the Contract Research Organisation (CRO) industry, with revenue declining to £24.2 million from £35.6 million year-over-year and EBITDA dropping to £3 million from £8.7 million. Management attributes this performance to sector-wide macroeconomic headwinds. However, the company's forward-looking indicators are strong, substantiating its optimistic guidance for growth in 2026. A key positive is the early success of its diversification strategy, with new service lines contributing £7.9 million in H1 revenue, a substantial increase from a minimal contribution previously. The company's future revenue visibility is supported by a £40 million contracted orderbook, approximately £7 million in new awards secured post-period, and a pipeline of customer proposals in H1 2025 that exceeded the aggregate value for the entire full-year 2024. The letter of intent for a pivotal Phase III human challenge trial with ILiAD Biotechnologies further signals the potential for high-value contracts. The reported cash reduction to £23.3 million is a direct result of strategic acquisitions (CRS and Cryostore) intended to bolster this diversification, while a new four-division corporate structure is designed to improve operational clarity and efficiency.

Key Decisions for Investors

• Investors should weigh the significant decline in H1 revenue and EBITDA against the strong forward-looking indicators, particularly the fact that the value of customer proposals in H1 2025 surpassed the total for FY24.
• The performance of the new diversified service lines, which generated £7.9 million in H1, should be monitored closely as the primary driver for achieving management's guided growth for 2026 amid industry headwinds.
• The progression of the letter of intent with ILiAD Biotechnologies for a pivotal Phase III trial represents a key potential catalyst; confirmation of a definitive contract would significantly de-risk future revenue projections.
• Consider the current trading as being 'in line with expectations' despite the year-on-year drop, focusing on the company's ability to convert its £40 million order book and robust pipeline into recognized revenue.